Author

R. Aggarwal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. Chou· 3 shared A. Foye· 2 shared E. J. Small· 2 shared F. Y. Feng· 2 shared A. Debebe· 1 shared A. P. Bidkar· 1 shared A. Ribas· 1 shared A. Vega-Crespo· 1 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Chou

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy

A. P. Bidkar, S. Wang, K. N. Bobba, E. Chan, S. Bidlingmaier, E. A. Egusa, R. Peter, U. Ali, N. Meher, A. Wadhwa, S. Dhrona, D. Beckford-Vera, Y. Su, R. Tang, L. Zhang, , R. R. Flavell

This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology

CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer

N. Zhao, k. Trepka, Y.-h. Wang, S. Chopra, N. Hooshdaran, H. Kim, J. Yang, J. Zhuo, S. Lim, K. K. Leung, E. Egusa, L. K. Zhang, A. Foye, J. Chou, F. Y. Feng, , R. Aggarwal

This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.

bioRxiv · Jun 17, 2021 · PreprintCancer Biology

A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples

T. Madan, B. Biswas, P. Varghese, R. Subedi, H. Pandit, S. Idicula-Thomas, I. Kundu, S. B. Rooge, R. Aggarwal, D. Tripathi, S. Kaur, E. Gupta, S. Gupta, U. Kishore

This study shows that a recombinant fragment of human SP-D inhibits SARS-CoV-2 spike protein binding to ACE-2 and reduces viral replication in clinical samples.

bioRxiv · Dec 18, 2020Immunology

Chronic Exposure to Palmitic Acid Downregulates AKT in Beta-Cells through Activation of mTOR

R. Aggarwal, Z. Peng, N. Zeng, J. Silva, L. He, J. Chen, A. Debebe, E. Stiles, C.-Y. Chen, B. L. Stiles

This study shows chronic palmitic acid exposure reduces AKT in beta-cells via mTOR activation, leading to cell cycle inhibition and T2D risk.

bioRxiv · Aug 11, 2020 · PreprintCell Biology

Cell-free DNA as a biomarker for prostate cancer: elevated concentration and decreased fragment size

E. Chen, C. L. Cario, L. Leong, K. Lopez, C. Marquez, C. Chu, P. S. Li, E. Oropeza, I. Tenggara, J. Cowan, J. P. Simko, J. M. Chan, T. Friedlander, A. W. Wyatt, R. Aggarwal, , J. S. Witte

This study finds that higher plasma cfDNA concentrations and smaller fragment sizes are associated with more advanced prostate cancer.

bioRxiv · Jul 26, 2020 · PreprintCancer Biology

Autoantibody landscape of advanced prostate cancer

W. S. Chen, W. A. Haynes, R. Waitz, K. Kamath, A. Vega-Crespo, R. Shrestha, M. Zhang, A. Foye, I. Baselga Carretero, I. Garcilazo Perez, M. Zhang, S. G. Zhao, M. Sjostrom, D. A. Quigley, J. Chou, , F. Y. Feng

This study characterizes the autoantibody landscape in metastatic castration-resistant prostate cancer using serum epitope repertoire analysis and identifies novel tumor-specific epitopes.

bioRxiv · May 2, 2020 · PreprintCancer Biology